Volume: 48 Issue: 1
Year: 2017, Page: 20-22,
Received: June 22, 2016 Accepted: June 27, 2016 Published: June 30, 2017
Twelve obese dogs with metabolic syndrome were treated with ezetimibe @ 0.1mg/ kg bodyweight for a period of 30 days. The variation in biochemical values and bodyweight after therapy is reported.
Keywords: Body condition score, obesity, canine metabolic syndrome, ezetimibe
Bergman, R.N., Kim, S.P., Catalano, K.J., Hsu, I.R., Chiu, J.D., Kabir, M., Hucking, K. and Ader, M. 2006. Why visceral fat is bad: mechanism of metabolic syndrome. Obes. Res. 14:16-19.
Davis, H.R., Pula, K.K., Alton, K.B., Burrier, R.E. and Watkins, R.W. 2001. The synergistic hypocholesterolemic activity of the potent cholesterolabsorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in dogs. Metabolism. 50: 1234-1241.
Gossellin, J., Wren, J.A. and Sunderland, S.L. 2007. Canine obesity: an overview. J. Vet. Pharmacol. Ther. 30: 1-10.
Hess, R.S., Saunders, H. and Van Winkle, T.J. 2000. Concurrent disorders in dogs with diabetes mellitus: 221 cases. J. Am. Vet.
Med. Ass. 217: 1166-1173.
Jeusette, I.C., Lhoest, E.T. and Istasse, L.P. 2005. Influence of obesity on plasma lipid and lipoprotein concentrations in
dogs. Am. J. Vet. Res. 66: 81-86.
Kaps, M. and Lamberson, W. 2009. Biostatistics for animal science- an introductory text. (2nd Ed.). CABI Head Office, Oxfordshire, United Kingdom, 504p.
Kawasumi, K., Suzuki, T., Fujiwara, M., Mori, N., Yamamoto, I. and Arai, T. 2012.New criteria for canine metabolic syndrome
in Japan.J. Anim. Vet. Adv.11: 4005- 4007.
Kosoglou, T., Meyer, I., Veltri, E.P., Statkevich, P., Yang, B., Zhu, Y., Mellars, L., Maxwell, S.E., Patrick, J.E., Cutler, D.L., Batra, V.K. and Affrime, M.B. 2000.Pharmacodynamic interactions between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.J. Clin. Pharmacol. 20: 303-328.
Laflamme, D.P. 1997. Development and validation of a body condition score system for dogs. Canine Pract. 22:10-15.
Loomba, R., Sirlin, C.B., Ang, B., Bettencourt, R., Jain, R., Salotti, J., Soaft, L., Hooker, L., Kono, Y., Bhutt, Y., Hernandez, L., Nguyen, P., Noureddin, M., Haufe, L., Hooker, C., Yin, M., Ehman, R., Lin, G.Y.,Valasek, M.A., Brenner, D.A. and Richards, L. 2015. Steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial. Hepatology. 61: 1239-1250.
Mohammadi, A., Yari, R., Farnoosh, G. and Oshaghi, E.A. 2014. Effect of ezetemibe on some biochemical factors and expression of intestinal scavenger receptor class B type I (SR-BI) in obsess mouse. Int. Res. J. Biological Sci. 3: 10-13.
Pandya, N., Santani, D. and Jain, S. 2006. Antioxidant activity of ezetimibe in hypercholesterolemic rats.Indian J.
Pharmacol. 38: 205-206. Pena, C., Sciarez, L., Bautista, I., Montoya, J.A. and Juste, M.C. 2008. Relationship between analytical values and canine obesity. J. Anim. Physiol. Anim. Nutr. 92: 324-325.
Tribuddharatana, T., Kongpiromchean, Y., Sridben, K. and Sriben, C. 2011. Biochemical alterations and their
relationships with the metabolic syndrome in canine obesity. Kasetsart J. 45: 622-628.